Drug
Irofulven clinical trials
Also written MGI-114 and 6-hydroxymethylacylfulvene.
- studies test it
- 20
- open now
- 0
- in phase 3
- 1
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 1998 (6)
| Year | Studies |
|---|---|
| 1998 | 6 |
| 1999 | 4 |
| 2000 | 3 |
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 17
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 15
National Cancer Institute (NCI) (5) · Eisai Inc. (4) · Memorial Sloan Kettering Cancer Center (2) · Allarity Therapeutics (1) · M.D. Anderson Cancer Center (1) · Alliance for Clinical Trials in Oncology (1) · New Approaches to Brain Tumor Therapy Consortium (1) · University of Colorado, Denver (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses irofulven is read from its arms, and is right about nine times in ten.
Testing it · 20
- Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)CompletedPhase 2Allarity TherapeuticsNCT03643107Written as Irofulven
- Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid TumorsCompletedPhase 1/2Eisai Inc.NCT00374660Written as Irofulven
- Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerCompletedPhase 2Eisai Inc.NCT00124527Written as Irofulven + capecitabine
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00053365Written as irofulven
- Irofulven in Treating Patients With Metastatic Colorectal CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT00003441Written as Irofulven (MGI-114)
- Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00003666Written as 6-hydroxymethylacylfulvene
- Study of Irofulven in Patients With Hormone-refractory Prostate CancerCompletedPhase 2Eisai Inc.NCT00124566Written as Irofulven
- Irofulven in Treating Patients With Metastatic or Recurrent Colorectal CancerWithdrawnPhase 2University of ChicagoNCT00003786Written as irofulven
- Chemotherapy in Treating Patients With Progressive or Recurrent Brain TumorsCompletedPhase 1/2New Approaches to Brain Tumor Therapy ConsortiumNCT00012038Written as irofulven
- 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00003390Written as irofulven
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerCompletedPhase 2National Cancer Institute (NCI)NCT00019552Written as irofulven
- Irofulven in Treating Patients With Stage IVB or Recurrent Cervical CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00005070Written as irofulven
- Irofulven in Treating Patients With Stage IV MelanomaCompletedPhase 2University of Colorado, DenverNCT00005968Written as irofulven
- Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial CancerCompletedPhase 2Gynecologic Oncology GroupNCT00005031Written as irofulven
- Irofulven in Treating Patients With Recurrent or Metastatic Gastric CancerCompletedPhase 2Cancer Therapeutics Research GroupNCT00062257Written as irofulven
- Irofulven in Treating Patients With Metastatic Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00003796Written as irofulven
- 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedPhase 1National Cancer Institute (NCI)NCT00003997Written as irofulven
- Irofulven in Treating Children With Recurrent or Refractory Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00003370Written as irofulven
- Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic CancerCompletedPhase 3Eisai Inc.NCT00033735Written as Irofulven
- Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic CancerCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT00003760Written as irofulven
Codes
What other systems call irofulven · ClinicalTrials.gg INT003944
- MeSH (NLM) C102714irofulvenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6B799IH05AIROFULVENConfirmed FDA, NLM, Wikidata
- Wikidata Q6072197irofulvenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1717IrofulvenOne source FDA
- DrugBank DB05786One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C102714 | irofulven | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6B799IH05A | IROFULVEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6072197 | irofulven | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1717 | Irofulven | One source FDA |
| DrugBank | DB05786 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.